Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lidocaine hydrochloride + neomycin sulfate + bacitracin zinc + polymyxin b
- Development stage
- Approved
- Lead developer
- Kenvue
- Modality
- Peptides, Small Molecules
- Administration
- Topical
01
Overview
Lidocaine hydrochloride + neomycin sulfate + bacitracin zinc + polymyxin B is a **topical first-aid antibacterial and local-anesthetic combination**. Bacitracin inhibits bacterial cell-wall synthesis, neomycin inhibits bacterial protein synthesis through the 30S ribosomal subunit, and polymyxin B disrupts susceptible bacterial outer membranes through interaction with lipopolysaccharide; lidocaine provides local analgesia by inhibiting neuronal sodium-channel-mediated impulse conduction. The combination is marketed in multiple nonprescription topical products and strengths, including ReCellTis Wound Cream, which contains bacitracin zinc, neomycin sulfate, polymyxin B sulfate, and lidocaine hydrochloride and is labeled for topical use on wounds such as cuts, scrapes, and burns. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8902aa55-547d-787f-e053-2a95a90a2289))
- Brand names
- ReCellTis
- Other names
- bacitracin zinc + neomycin sulfate + polymyxin b sulfate + lidocaine hydrochloride
02
Targets
30S A-site (Bacterial ribosomal 30S A-site)C55-PP (Undecaprenyl pyrophosphate)Lipid A phosphate (Lipid A phosphate groups)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on lidocaine hydrochloride + neomycin sulfate + bacitracin zinc + polymyxin b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lidocaine hydrochloride + neomycin sulfate + bacitracin zinc + polymyxin b.